Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling, which may result to decreased growth of cancer cells.

SparkCures ID 31
Developed By Pharmacyclics
Generic Name Ibrutinib
Additional Names Imbruvica, PCI-32765
Treatment Classifications
  • Bruton's Tyrosine Kinase (BTK) Inhibitor

Clinical Trials


There are no resources, links or videos to display for this treatment.